Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Phase III Trial | Completed
Conditions : Acromegaly
Clinical trials
Our biotech mindset, combined with the scale and advantages of a global pharmaceutical company, has established us as a development powerhouse in our core areas of focus. A global network of healthcare professionals help us test new treatments and ensure their efficacy and safety by conducting studies called clinical trials.
We have therapeutically-aligned teams, global expertise in regulatory affairs, patient safety and medical affairs, as well as a proven ability to bring new, life changing therapies successfully through clinical development.
The following list displays information about clinical trials sponsored by Ipsen.
Only interventional studies that are not yet recruiting, recruiting, active not recruiting or completed since 2015 will be displayed.
The study results will be available on clintrial.gov from 12 months after the end of the study.
To learn more about available studies, go on: https://clinicaltrials.gov/.
Last updated date: 05/11/2018
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Phase I/II Trial | Completed
Conditions : Acromegaly
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
Phase II Trial | Recruiting
Conditions : Pancreatic Tumours, Midgut Neuroendocrine Tumours
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Phase IV Trial | Active, not recruiting
Conditions : Prostate Cancer
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
Phase III Trial | Active, not recruiting
Conditions : Neuroendocrine Tumors
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Phase III Trial | Recruiting
Conditions : Endometriosis
Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea
Phase I Trial | Completed
Conditions : Chronic Functional Diarrhea of Unknown Origin
Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
Phase I Trial | Completed
Conditions : Hepatic Impairment
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
Phase I Trial | Completed
Conditions : Renal Impairment
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Phase II Trial | Recruiting
Conditions : Gastro-Enteropancreatic Neuroendocrine Tumor
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
Phase II Trial | Not Yet recruiting
Conditions : Breast Cancer
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in NETs
Phase I/II Trial | Recruiting
Conditions : Neuroendocrine Tumors
Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.
Phase I/II Trial | Recruiting
Conditions : Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck, Bone Cancer, Advanced Cancer, Recurrent Disease, Metastatic Tumours
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
Phase III Trial | Recruiting
Conditions : Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
Phase III Trial | Recruiting
Conditions : Urinary Incontinence, Overactive Bladder
Dysport in Hallux Abducto Valgus (HAV) Phase IIa
Phase II Trial | Recruiting
Conditions : Hallux Abductovalgus
Dysport in Post-Surgical Neuralgia (RESPITE)
Phase II Trial | Not Yet recruiting
Conditions : Chronic Scar Pain
Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
Phase IV Trial | Recruiting
Conditions : Acute Diarrhoea
Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)
Phase IV Trial | Completed
Conditions : Spastic Hemiparesis
Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy
Phase III Trial | Recruiting
Conditions : Digestive System Disease
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Phase I Trial | Active, not recruiting
Conditions : Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
Phase II/III Trial | Recruiting
Conditions : Small Cell Lung Cancer
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Phase I/II Trial | Recruiting
Conditions : Pancreatic Cancer
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Phase III Trial | Active, not recruiting
Conditions : Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
Phase III Trial | Completed
Conditions : Glabellar Lines
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
Phase III Trial | Completed
Conditions : Moderate to Severe Glabellar Lines
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
Phase III Trial | Completed
Conditions : Glabellar Lines